Plasma SMOC2 Predicts Prognosis in Patients with Heart Failure: A Prospective Cohort
Xin Chen,Xing Zhong,Dan Luo,Yuhua Lei,Rui Huang
DOI: https://doi.org/10.2147/ijgm.s445457
IF: 2.145
2024-04-30
International Journal of General Medicine
Abstract:Xin Chen, 1– 3, &ast Xing Zhong, 1, 4, &ast Dan Luo, 1– 3, &ast Yuhua Lei, 1– 3 Rui Huang 1– 3 1 Cardiovascular Disease Center, The Central Hospital of Enshi Tujia and Miao Autonomous Prefecture, Enshi, Hubei Province, People's Republic of China; 2 Hubei Selenium and Human Health Institute, The Central Hospital of Enshi Tujia and Miao Autonomous Prefecture, Enshii, Hubei Province, People's Republic of China; 3 Hubei Provincial Key Laboratory of Selenium Resources and Bio applications, Enshii, Hubei Province, People's Republic of China; 4 Department of Medicine, Hubei Minzu University, Enshi, Hubei Province, People's Republic of China &astThese authors contributed equally to this work Correspondence: Yuhua Lei; Rui Huang, Email ; Background: Heart failure (HF) is a chronic disease with a poor prognosis, making it extremely important to assess the prognosis of patients with HF for accurate treatment. Secreted modular calcium-binding protein 2 (SMOC2) is a cysteine-rich acidic secreted protein that plays a pathophysiological role in many diseases, including regulation of vascular growth factor activity. It has previously been found that SMOC2 plays an essential role in cardiac fibrosis in our previous preclinical study, but whether it can be used as a clinical marker in heart failure patients remains unclear. The purpose of this research was to evaluate the correlation between plasma levels of SMOC2 and the prognosis for individuals with HF. Methods: HF patients diagnosed with ischemic cardiomyopathy were enrolled from January to December 2021. Baseline plasma levels of SMOC2 were measured after demographic and clinical features were collected. Linear and nonlinear multivariate Cox regression models were used to determine the association between plasma SMOC2 and patient outcomes during follow-up. All analysis was performed using SPSS, EmpowerStats, and R software. Results: The study included 188 patients, and the average follow-up time was 489.5± 88.3 days. The plasma SMOC2 concentrations were positively correlated with N-terminal pro-B-type Natriuretic Peptide (NT-proBNP), left ventricular end-diastolic diameter (LVEDd), and length of hospital stay and were negatively correlated with left ventricular ejection fraction (LVEF) at baseline. A total of 53 patients (28.2%) were rehospitalized due to cardiac deterioration, 14 (7.4%) died, and 37 (19.7%) developed malignant arrhythmias. A fully adjusted multivariate COX regression model showed that SMOC2 is associated with readmission (HR = 1.02, 95% CI:1.012– 1.655). A significant increase in rehospitalization risk was observed in group Q2 (HR =1.064, 95% CI: 1.037, 3.662, p=0.005) and group Q3 (HR =1.085, 95% CI:1.086, 3.792, p=0.009) in comparison with group Q1. The p for trend also shows a linear correlation across the three models (P < 0.001). SMOC2 was associated with the severity of HF in patients, but not with all-cause deaths and arrhythmias during follow-up. Conclusion: Plasma SMOC2 is associated with the severity of HF and readmission rate, and is a good predictor of the risk of readmission in patients. Keywords: SMOC2, heart failure, ischemic cardiomyopathy, readmission rate, myocardial fibrosis Heart failure (HF) is a complex clinical syndrome with high prevalence and mortality caused by physiological and neurohormonal changes caused by abnormal cardiac structure or function, which has seriously increased the global medical burden. 1 Wheezing, edema, arrhythmias, and cardiac enlargement are some of the clinical manifestations of HF. Left ventricular ejection fraction (LVEF), ventricular structure, body mass index(BMI), and biomarkers such as brain natriuretic peptide, troponin, and C-reactive protein are commonly used clinically to assess heart disease. 2,3 There is still much to be discovered about the prognosis of HF, as it is an extremely complex pathophysiological process. Secreted modular calcium-binding protein 2 (SMOC2) is a member of the cysteine-rich acidic secretory protein (SPARC) in the stromal cell protein family, which contains an extracellular calcium-binding (EC) domain and a typical domain with 10 cysteines. 4 SMOC2 interacts with matrix proteins, cell surface receptors, cytokines, proteasomes, and other effector molecules, which can regulate the interaction of cells and cell matrix, as well as the activity of vascular growth factors. 5,6 The SMOC2 protein may serve as a marker for HF, and interventions targeting SMOC2 may be effective in treating heart disorders. For example, Wilk et al 7 in 2007 studied mRNA expressions in left and rig -Abstract Truncated-
medicine, general & internal